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Abstract
Background: Increased Neutrophil-to-Lymphocyte Ratio (NLR) is an independent risk factor for 
mortality in Covid-19 patients and is considered as an early warning sign of Covid-19 severity. This 
study aimed to observe the differences in NLR at admission between patients with mild, moderate, 
and severe symptoms of Covid-19 treated in a referral hospital in Banda Aceh, Indonesia.
Methods: A total of 114 patients with Covid-19 admitted to a referral hospital in Banda Aceh, 
Indonesia, during March–September 2020 were included in this study. Demographic information and 
baseline laboratory data, including the NLR, were collected. Descriptive and inferential statistics were 
used to analyze the data. 
Results: The median NLR at admission was higher among patients with moderate to severe symptoms 
than those with mild symptoms [6.54 (2.80–97.00, IQR 4.81–9.44) vs 2.27 (0.79–5.07, IQR 1.43-2.98), 
p <0.001]. Covid-19 patients who died had a higher NLR than those who survived [10.88 (4.17–
47.50, IQR 7.00–15.17) vs 6.15 (2.80–97.00, IQR 4.63–8.50), p 0.02]. Patients with moderate-severe 
symptoms had an initial NLR of 4.63–8.50 and decreased to 2.75–5.43 at the end of the treatment had 
a greater chance of survival. There was an increased probability of death in patients with moderate-
severe symptoms whose initial NLR was 7.00–15.17, which was then elevated to 14.33–23.25.
Conclusions: Different NLR at admission is seen among Covid-19 patients with mild and moderate-
severe symptoms, leading to significantly different outcomes. The NLR can be used as a simple 
parameter to determine the severity of the disease and predict the outcome of Covid-19 patients. 
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Introduction
The novel coronavirus, the SARS-CoV-2, was 
first recognized in the city of Wuhan, China 
in December 2019. The disease caused by the 
virus, the Covid-19, since then become a global 
emerging concern due to its rapid outbreak, 
fast worldwide spread, and high fatality rate. 
By the end of December 2020, the World 
Health Organization (WHO) confirmed more 
than 80 million positive cases and more than 
1.7 million death globally.1 In Indonesia, more 
than 700.000 cases and more than 21,000 
death have been confirmed.2 Meanwhile, in the 
province of Aceh, more than 8,700 cases, 344 
death, and more than 7,400 have recovered 
from the disease by the end of December 2020.3 
Studies related to Covid-19 have been focused 
on various aspects of the disease, ranging 
from clinical factors, patients’ condition and 
outcome as well as the community perception, 
attitude, and behavior toward the disease. 
Description of clinical factors of the disease 
is important to help clinicians in treating and 
predicting the outcome of treatment. 
Neutrophil to Lymphocyte Ratio (NLR) is 
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moderate symptoms, severe symptoms with 
pneumonia, and critical.15 Mild Covid-19 was 
defined as patients with viral respiratory 
tract infection with non-specific symptoms 
(fever, malaise, cough with/without sputum, 
anorexia, muscle pain, sore throat, shortness 
of breath, mild pneumonia, nasal congestion, 
headache, diarrhea, nausea, and vomiting). 
Moderate Covid-19 was defined as a patient 
with pneumonia without severe pneumonia, 
no need for oxygen supplementation. Severe 
Covid-19 was defined as pneumonia with 
either respiratory rate more than 30/minutes, 
respiratory distress, oxygen saturation <93% 
in room air, PaO2/FiO2 ratio < 300.15
All patients with Covid-19, aged 18 above, 
admitted to the hospital between March to 
September 2020, were included in the study. 
Patients with an incomplete blood test, 
suffering from cancer, or already had blood 
problems prior to Covid-19 were excluded 
from the study. 
Secondary data on the patient’s clinical 
features were generated from the hospital 
medical record, including the patient’s 
diagnosis and its severity during admission, 
blood test examination results such as 
neutrophil and lymphocyte, duration of 
hospitalization, and outcome of the treatment.
The characteristics of the patients were 
described using the frequency and percentage 
parameters. For numerical data, the normality 
test was performed first using the Shapiro 
Wilk test, then descriptively presented in the 
form of mean and standard deviation if the 
data were normally distributed or median 
and ranges (minimum-maximum) if the data 
were not normally distributed. To observe 
the difference in the neutrophil lymphocyte 
ratio in Covid-19 patients with mild and 
moderate-severe symptoms, the unpaired 
t-test was used, if the data were normally 
distributed and the Mann Whitney test if the 
data were not normally distributed. The result 
of the statistical test was significant if p<0.05. 
The analysis was performed using the SPSS 
statistical program.
Results
The characteristics of patients with moderate 
to severe symptoms of Covid-19 were older, 
spent the longer duration of hospitalization, 
a higher proportion of comorbid including 
hypertension, diabetes, health problem 
and secondary infection, a higher mean of 
neutrophil percentage but a lower mean of 
lymphocyte percentage compared to the 
an independent risk factor of mortality among 
hospitalized Covid-19 patients.4 The NLR is a 
reflection of the balance between the innate 
immune response (neutrophils) and adaptive 
immunity (lymphocytes). NLR is calculated by 
dividing the absolute number of neutrophils 
by the absolute number of lymphocytes or 
the percentage of neutrophils divided by 
the percentage of lymphocytes from the 
peripheral blood sample.5 Thus, the NLR value 
can be obtained immediately by carrying out 
routine blood tests upon admission to the 
hospital. The physician can identify the risks in 
the early stages of Covid-19 patients; thus, the 
treatment can be adjusted to reduce hospital 
deaths.
During admission, a high level of NLR 
defines the severity of the diseases and 
predicts a poor prognosis.6-8 Increased NLR in 
Covid-19 patients, along with age and white 
blood cells count are also associated with 
a higher rate of mortality,9 and it remains as 
the independent predictor of critical illness 
of Covid-19.10 However, there is a study that 
has found a non-significant contribution of 
NLR toward the death in Covid-19 cases.11 
Nevertheless, it is generally approved that 
NLR can be used as an early warning signal 
for the deterioration of covid-19 patient 
condition12 and high NLR can be considered 
as a prognostic marker of diseases severity in 
patients with Covid-19.13,14 Examination the 
NLR is, therefore, an important step in the 
treatment of Covid-19 patients.
Furthermore, the vast majority of earlier 
reports come from developed countries, 
where the treatment of patients is at the 
most sophisticated level. The report from 
developing countries such as Indonesia is 
limited. Therefore, this study aimed to observe 
the differences of NCL between mild, and 
moderate to severe symptoms of Covid-19 
admitted to a Covid-19 provincial referral 
hospital in the province of Aceh, Indonesia.
Methods
This retrospective cross-sectional study was 
conducted at the Respiratory Intensive Care 
Unit (RICU) and Special Covid-19 nursing ward 
of a general - teaching hospital in Banda Aceh, 
Indonesia. The hospital is the main provincial 
referral hospital that serves approximately 5 
million population in the province. 
The Ministry of Health Republic of Indonesia 
had divided the severity of Covid-19 symptoms 
into five categories; which were no symptoms, 
mild symptoms with no complication, 
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Note: at–test, bMann Whitney U test, cChi Square, dFisher Exact, *significant at <0.05
patients with mild symptoms of Covid-19, as 
shown in Table 1.
A higher mortality rate was also found 
among patients with moderate to severe 
symptoms in this study (16.6%). The patients 
who died had significantly, (p=0.02) higher 
NLR than surviving patients [10.88 (4.17–
47.50, IQR 7.00–15.17)] vs [6.15 (2.80–97.00, 
IQR 4.63–8.50)]. The median of NLR during 
admission was 2.27 (IQR 1.43–2.98) among 
patients with mild symptoms, while among 
moderate to severe symptoms patients was 
6.54 (IQR 4.81–9.44). Before the hospital 
discharge, the median NLR was 1.92 (IQR 
1.39–2.52) among those with mild symptoms 
and 4.14 (IQR 2.91–8.50) among patients with 
moderate to severe symptoms, as shown in 
Table 2.
Discussion
A higher level of NLR among patients with 
moderate to severe symptoms compared to 
those with mild symptoms has been found 
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predictive and prognostic nomogram which 
could guide the clinicians to shorten the course 
of the disease, fasten the recovery, alleviate 
the shortage of medical supplies and lower 
mortality rate in Covid-19 patients.20
Meanwhile, none of those mild symptoms 
died but have recovered following the 
treatment. The 16.6% mortality rate in this 
study is significantly higher than reported in 
an epidemiological study, where only 6.3% of 
death is found among Covid-19 patients with 
moderate and severe cases, administered in 
Brazilian hospitals.18 The reason for a higher 
mortality rate in this study population is 
not well understood, since other possible 
determinants, such as age and other physical 
problems, have not been examined in this 
study.
Our study has several limitations. This study 
did not evaluate the correlation of comorbidity 
in NLR such as diabetes and secondary infection, 
which could also increase neutrophil. Second, 
this study did not evaluate the changes of NLR 
and severity of the illness on a day-to-day 
basis. Moreover, we have retrieved secondary 
data from the medical records where some 
laboratory data were missing. Further study 
on the correlation among other demographic 
factors toward mortality of Covid-19, which 
are not specifically investigated in this study, 
could be conducted.
In conclusion, this study has highlighted 
several important clinical findings. The NLR 
could be used as one of the standpoints for the 
treatment of patients with suspected Covid-19 
during admission. A higher level of NLR 
tends to get severe and poor prognosis, thus 
special attention and treatment are required. 
Furthermore, the NLR can be used as a simple 
parameter to help determine the severity of the 
disease and predict the outcome of Covid-19.
in the present study, supporting the earlier 
findings.6-8 High level of NLR during admission 
should become an alarming sign of the patients’ 
prognosis, thus the physicians require to treat 
them differently than lower NLR patients. The 
patients with a higher level of NLR that usually 
come with moderate to severe symptoms, such 
as fever, cough, respiratory tract infection–
pneumonia, oxygen saturation lower than 
93%, usually require immediate treatment at 
the respiratory intensive care unit. Immediate 
treatment in this unit could improve the 
outcome of the treatment.16,17
The changes of NLR value during admission 
in moderate to severe symptom Covid-19 
compared to the NLR value on hospital 
discharge could predict the outcome. The 
chance of survival is greater in moderate to 
severe symptom Covid-19, whose NLR value is 
decreasing. In contrast, death risk is greater in 
those who have NLR elevation. The changing 
of NLR during the course of the disease 
could be reflected as inflammation process 
alteration in line with clinical improvement 
or deterioration. In deteriorated patients, 
there is an increase in inflammation, reflected 
by neutrophil elevation and declined of 
lymphocyte which resulted in NLR elevation. 
Until now, there is no study addressing the 
changing of NLR along the course of Covid-19 
in Indonesia.
The higher mortality rate among patients 
with moderate to severe symptoms in this 
study (16.7%) is consistent with previous 
reports, which also suggest the importance 
of prompt treatment of those with moderate 
to severe symptoms.18,19 Higher NLR among 
patients who died in this study confirms that 
NLR is a single independent risk factor of 
mortality in Covid-19 patients.4 Scoring the 
NLR is therefore considered as a powerful 
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